Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 2
2008 2
2014 1
2016 3
2017 2
2018 1
2020 2
2021 4
2022 4
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum.
van der Sluis TC, Beyrend G, van der Gracht ETI, Abdelaal T, Jochems SP, Belderbos RA, Wesselink TH, van Duikeren S, van Haften FJ, Redeker A, Ouboter LF, Beyranvand Nejad E, Camps M, Franken KLMC, Linssen MM, Hohenstein P, de Miranda NFCC, Mei H, Bins AD, Haanen JBAG, Aerts JG, Ossendorp F, Arens R. van der Sluis TC, et al. Among authors: bins ad. Cell Rep Med. 2023 Mar 21;4(3):100939. doi: 10.1016/j.xcrm.2023.100939. Epub 2023 Feb 15. Cell Rep Med. 2023. PMID: 36796366 Free PMC article.
Diagnostic liquid biopsy biomarkers in renal cell cancer.
Zieren RC, Zondervan PJ, Pienta KJ, Bex A, de Reijke TM, Bins AD. Zieren RC, et al. Among authors: bins ad. Nat Rev Urol. 2024 Mar;21(3):133-157. doi: 10.1038/s41585-023-00818-y. Epub 2023 Sep 27. Nat Rev Urol. 2024. PMID: 37758847 Review.
Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.
de Ruiter BM, van Hattum JW, Lipman D, de Reijke TM, van Moorselaar RJA, van Gennep EJ, Maartje Piet AH, Donker M, van der Hulle T, Voortman J, Oddens JR, Hulshof MCCM, Bins AD. de Ruiter BM, et al. Among authors: bins ad. Eur Urol. 2022 Nov;82(5):518-526. doi: 10.1016/j.eururo.2022.07.009. Epub 2022 Aug 3. Eur Urol. 2022. PMID: 35933242 Free article. Clinical Trial.
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Geurts BS, Battaglia TW, van Berge Henegouwen JM, Zeverijn LJ, de Wit GF, Hoes LR, van der Wijngaart H, van der Noort V, Roepman P, de Leng WWJ, Jansen AML, Opdam FL, de Jonge MJA, Cirkel GA, Labots M, Hoeben A, Kerver ED, Bins AD, Erdkamp FGL, van Rooijen JM, Houtsma D, Hendriks MP, de Groot JB, Verheul HMW, Gelderblom H, Voest EE. Geurts BS, et al. Among authors: bins ad. BMC Cancer. 2023 Mar 4;23(1):205. doi: 10.1186/s12885-023-10663-2. BMC Cancer. 2023. PMID: 36870947 Free PMC article.
Intradermal vaccination by DNA tattooing.
van den Berg JH, Oosterhuis K, Schumacher TN, Haanen JB, Bins AD. van den Berg JH, et al. Among authors: bins ad. Methods Mol Biol. 2014;1143:131-40. doi: 10.1007/978-1-4939-0410-5_9. Methods Mol Biol. 2014. PMID: 24715286
30 results